Accueil > Version française > Valorisation - LST > Offres de technologies


L467 : Bacterial efflux pumps inhibitors for a new anti-infective therapy

technology offers

Lyon Science Transfert offers to grant patent license and looks for industrial partners.

DETAILED DESCRIPTION

The laboratory has identified 2 families of molecules inhibiting bacterial efflux pumps and showing or not an additional antibacterial activity. These new molecules potentiate fluoroquinolone activity (ciprofloxacine and norfloxacine) by inhibiting NorA efflux pumps of Staphylococcus aureus and Enterococcus faecalis. Easily obtained in large quantities, they are derived from flavonoids which are non toxic natural compounds of vegetal origin. Quantities of antibiotics will be decreased when used in association with these new inhibitors and treatment’s effectiveness even against GRAM+ resistant bacteria will be strengthened. Emergence of multidrug resistant bacterial strains will be slowed down.


ADVANTAGES / NOVELTY
  • Fluoroquinolone antibiotic activity strengthened against GRAM + resistant bacteria.
  • No toxicity in vitro and in vivo.
  • Effective synthesis and in large quantities.

APPLICATIONS

Thérapie anti-infectieuse : traitement antibiotique


RESEARCH TEAM

Anne Doléans-Jordheim 
Laboratoire d'Ecologie Microbienne, Equipe « Bactéries Pathogènes Opportunistes et Environnement » 
UMR 5557, CNRS-UCBL-UJF

Your technology officer
Christine Duarte
christine.duarte@universite-lyon.fr
Tel. +33(0)4 37 37 42 96

Thématique : Biology-Health, Drug discovery